glp 1 for kidney disease GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1 RAs, Other Agents, Underused
Description
In a recent retrospective study based on a nationwide multicenter database of electronic health records of 113 million United States patients, GLP-1RAs, compared with insulin, were associated with a significant risk reduction in 10 of 13 obesity-associated cancers, including pancreatic and colorectal cancer
N Engl J Med 2012;366:493-501.ArticlePubMed 91
10.1007/s12031-007-9002-1 28
The FDA does not approve nor review compounded products for safety, effectiveness, or quality
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity
Louis personal injury lawsuit case consultation today
